Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Am J Physiol Regul Integr Comp Physiol ; 322(6): R467-R485, 2022 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-35348007

RESUMEN

Hypertension characterized by low circulating renin activity accounts for roughly 25%-30% of primary hypertension in humans and can be modeled experimentally via deoxycorticosterone acetate (DOCA)-salt treatment. In this model, phenotypes develop in progressive phases, although the timelines and relative contributions of various mechanisms to phenotype development can be distinct between laboratories. To explore interactions among environmental influences such as diet formulation and dietary sodium (Na) content on phenotype development in the DOCA-salt paradigm, we examined an array of cardiometabolic endpoints in young adult male C57BL/6J mice during sham or DOCA-salt treatments when mice were maintained on several common, commercially available laboratory rodent "chow" diets including PicoLab 5L0D (0.39% Na), Envigo 7913 (0.31% Na), Envigo 2920x (0.15% Na), or a customized version of Envigo 2920x (0.4% Na). Energy balance (weight gain, food intake, digestive efficiency, and energy efficiency), fluid and electrolyte homeostasis (fluid intake, Na intake, fecal Na content, hydration, and fluid compartmentalization), renal functions (urine production rate, glomerular filtration rate, urine Na excretion, renal expression of renin, vasopressin receptors, aquaporin-2 and relationships among markers of vasopressin release, aquaporin-2 shedding, and urine osmolality), and blood pressure, all exhibited changes that were subject to interactions between diet and DOCA-salt. Interestingly, some of these phenotypes, including blood pressure and hydration, were dependent on nonsodium dietary components, as Na-matched diets resulted in distinct phenotype development. These findings provide a broad and robust illustration of an environment × treatment interaction that impacts the use and interpretation of a common rodent model of low-renin hypertension.


Asunto(s)
Acetato de Desoxicorticosterona , Hipertensión , Animales , Acuaporina 2 , Presión Sanguínea/fisiología , Desoxicorticosterona/farmacología , Acetato de Desoxicorticosterona/farmacología , Dieta , Hipertensión/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Renina/metabolismo , Sodio/metabolismo
2.
Am J Physiol Regul Integr Comp Physiol ; 318(5): R855-R869, 2020 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-32186897

RESUMEN

Angiotensin II (ANG II) Agtr1a receptor (AT1A) is expressed in cells of the arcuate nucleus of the hypothalamus that express the leptin receptor (Lepr) and agouti-related peptide (Agrp). Agtr1a expression in these cells is required to stimulate resting energy expenditure in response to leptin and high-fat diets (HFDs), but the mechanism activating AT1A signaling by leptin remains unclear. To probe the role of local paracrine/autocrine ANG II generation and signaling in this mechanism, we bred mice harboring a conditional allele for angiotensinogen (Agt, encoding AGT) with mice expressing Cre-recombinase via the Lepr or Agrp promoters to cause cell-specific deletions of Agt (AgtLepr-KO and AgtAgrp-KO mice, respectively). AgtLepr-KO mice were phenotypically normal, arguing against a paracrine/autocrine AGT signaling mechanism for metabolic control. In contrast, AgtAgrp-KO mice exhibited reduced preweaning survival, and surviving adults exhibited altered renal structure and steroid flux, paralleling previous reports of animals with whole body Agt deficiency or Agt disruption in albumin (Alb)-expressing cells (thought to cause liver-specific disruption). Surprisingly, adult AgtAgrp-KO mice exhibited normal circulating AGT protein and hepatic Agt mRNA expression but reduced Agt mRNA expression in adrenal glands. Reanalysis of RNA-sequencing data sets describing transcriptomes of normal adrenal glands suggests that Agrp and Alb are both expressed in this tissue, and fluorescent reporter gene expression confirms Cre activity in adrenal gland of both Agrp-Cre and Alb-Cre mice. These findings lead to the iconoclastic conclusion that extrahepatic (i.e., adrenal) expression of Agt is critically required for normal renal development and survival.


Asunto(s)
Glándulas Suprarrenales/metabolismo , Proteína Relacionada con Agouti/metabolismo , Angiotensinógeno/metabolismo , Núcleo Arqueado del Hipotálamo/metabolismo , Metabolismo Energético , Riñón/metabolismo , Receptores de Leptina/metabolismo , Glándulas Suprarrenales/crecimiento & desarrollo , Proteína Relacionada con Agouti/deficiencia , Proteína Relacionada con Agouti/genética , Angiotensinógeno/deficiencia , Angiotensinógeno/genética , Animales , Núcleo Arqueado del Hipotálamo/crecimiento & desarrollo , Comunicación Autocrina , Femenino , Regulación del Desarrollo de la Expresión Génica , Riñón/crecimiento & desarrollo , Masculino , Ratones Noqueados , Miocardio/metabolismo , Comunicación Paracrina , Receptores de Leptina/deficiencia , Receptores de Leptina/genética , Albúmina Sérica/genética , Albúmina Sérica/metabolismo , Transducción de Señal
3.
Am J Physiol Renal Physiol ; 311(2): F395-403, 2016 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-27252490

RESUMEN

Renal ischemia-reperfusion (I/R) in male rats causes reductions in plasma testosterone, and infusion of testosterone 3 h postreperfusion is protective. We tested the hypotheses that acute high doses of testosterone promote renal injury after I/R, and that acute low-dose testosterone is protective by the following: 1) increasing renal IL-10 and reducing TNF-α; 2) its effects on nitric oxide; and 3) reducing intrarenal T-cell infiltration. Rats were subjected to renal I/R, followed by intravenous infusion of vehicle or testosterone (20, 50, or 100 µg/kg) 3 h postreperfusion. Low-dose testosterone (20 µg/kg) reduced plasma creatinine, increased nitrate/nitrite excretion, increased intrarenal IL-10, and reduced intrarenal TNF-α, whereas 50 µg/kg testosterone failed to reduce plasma creatinine, increased IL-10, but failed to reduce TNF-α. A higher dose of testosterone (100 mg/kg) not only failed to reduce plasma creatinine, but significantly increased both IL-10 and TNF-α compared with other groups. Low-dose nitro-l-arginine methyl ester (1 mg·kg(-1)·day(-1)), given 2 days before I/R, prevented low-dose testosterone (20 µg/kg) from protecting against I/R injury, and was associated with lack of increase in intrarenal IL-10. Intrarenal CD4(+) and CD8(+) T cells were significantly increased with I/R, but were attenuated with low-dose testosterone, as were effector T helper 17 cells. The present studies suggest that acute, low-dose testosterone is protective against I/R AKI in males due to its effects on inflammation by reducing renal T-cell infiltration and by shifting the balance to favor anti-inflammatory cytokine production rather than proinflammatory cytokines.


Asunto(s)
Interleucina-10/metabolismo , Enfermedades Renales/prevención & control , Riñón/metabolismo , Daño por Reperfusión/prevención & control , Linfocitos T/efectos de los fármacos , Testosterona/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismo , Animales , Creatina/sangre , Citocinas/biosíntesis , Inhibidores Enzimáticos/uso terapéutico , Enfermedades Renales/patología , Masculino , NG-Nitroarginina Metil Éster/uso terapéutico , Nitratos/sangre , Óxido Nítrico Sintasa/antagonistas & inhibidores , Nitritos/sangre , Ratas , Ratas Sprague-Dawley , Daño por Reperfusión/patología , Testosterona/administración & dosificación , Células Th17/efectos de los fármacos
4.
Hypertension ; 76(3): 943-952, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32755410

RESUMEN

Polycystic ovary syndrome, the most common endocrine disorder in women of reproductive age, is characterized by hyperandrogenemia, obesity, insulin resistance, and elevated blood pressure. However, few studies have focused on the consequences of pregnancy on postmenopausal cardiovascular disease and hypertension in polycystic ovary syndrome women. In hyperandrogenemic female (HAF) rats, the hypothesis was tested that previous pregnancy protects against age-related hypertension. Rats were implanted with dihydrotestosterone (7.5 mg/90 days, beginning at 4 weeks and continued throughout life) or placebo pellets (controls), became pregnant at 10 to 15 weeks, and pups were weaned at postnatal day 21. Dams and virgins were then aged to 10 months (still estrous cycling) or 16 months (postcycling). Although numbers of offspring per litter were similar for HAF and control dams, birth weights were lower in HAF offspring. At 10 months of age, there were no differences in blood pressure, proteinuria, nitrate/nitrite excretion, or body composition in previously pregnant HAF versus virgin HAF. However, by 16 months of age, despite no differences in dihydrotestosterone, fat mass/or lean mass/body weight, previously pregnant HAF had significantly lower blood pressure and proteinuria, higher nitrate/nitrite excretion, with increased intrarenal mRNA expression of endothelin B receptor and eNOS (endothelial nitric oxide synthase), and decreased ACE (angiotensin-converting enzyme), AT1aR (angiotensin 1a receptor), and endothelin A receptor than virgin HAF. Thus, pregnancy protects HAF rats against age-related hypertension, and the mechanism(s) may be due to differential regulation of the nitric oxide, endothelin, and renin-angiotensin systems. These data suggest that polycystic ovary syndrome women who have experienced uncomplicated pregnancy may be protected from postmenopausal hypertension.


Asunto(s)
Hiperandrogenismo , Hipertensión , Óxido Nítrico Sintasa de Tipo III/metabolismo , Obesidad , Síndrome del Ovario Poliquístico , Posmenopausia/fisiología , Receptor de Endotelina B/metabolismo , Animales , Presión Sanguínea/fisiología , Femenino , Regulación de la Expresión Génica , Hiperandrogenismo/etiología , Hiperandrogenismo/metabolismo , Hipertensión/etiología , Hipertensión/metabolismo , Hipertensión/prevención & control , Riñón/metabolismo , Obesidad/metabolismo , Obesidad/prevención & control , Síndrome del Ovario Poliquístico/complicaciones , Síndrome del Ovario Poliquístico/metabolismo , Síndrome del Ovario Poliquístico/fisiopatología , Embarazo , Factores Protectores , Ratas , Sistema Renina-Angiotensina/fisiología
5.
Physiol Rep ; 5(20)2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29051304

RESUMEN

Polycystic ovary syndrome (PCOS) is the most common endocrine and reproductive disorder in premenopausal women, characterized by hyperandrogenemia, metabolic syndrome, and inflammation. Women who had PCOS during their reproductive years remain hyperandrogenemic after menopause. The consequence of chronic hyperandrogenemia with advanced aging has not been studied to our knowledge. We have characterized a model of hyperandrogenemia in female rats and have aged them to 22-25 months to mimic advanced aging in hyperandrogenemic women, and tested the hypothesis that chronic exposure to hyperandrogenemia with aging has a deleterious effect on renal function. Female rats were chronically implanted with dihydrotestosterone pellets (DHT 7.5 mg/90 days) that were changed every 85 days or placebo pellets, and renal function was measured by clearance methods. Aging DHT-treated females had a threefold higher level of DHT with significantly higher body weight, mean arterial pressure, left kidney weight, proteinuria, and kidney injury molecule-1 (KIM-1), than did age-matched controls. In addition, DHT-treated-old females had a 60% reduction in glomerular filtration rate, 40% reduction in renal plasma flow, and significant reduction in urinary nitrate and nitrite excretion (UNOxV), an index of nitric oxide production. Morphological examination of kidneys showed that old DHT-treated females had significant focal segmental glomerulosclerosis, global sclerosis, and interstitial fibrosis compared to controls. Thus chronic hyperandrogenemia that persists into old age in females is associated with renal injury. These data suggest that women with chronic hyperandrogenemia such as in PCOS may be at increased risk for development of chronic kidney disease with advanced age.


Asunto(s)
Envejecimiento/patología , Hiperandrogenismo/fisiopatología , Riñón/fisiopatología , Síndrome del Ovario Poliquístico/fisiopatología , Animales , Moléculas de Adhesión Celular/metabolismo , Femenino , Fibrosis , Tasa de Filtración Glomerular , Riñón/metabolismo , Riñón/patología , Ratas , Ratas Sprague-Dawley
6.
Clin Hemorheol Microcirc ; 67(2): 159-172, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28800323

RESUMEN

BACKGROUND: Interaction of von Willebrand factor (VWF) with circulating platelets is the trigger for thrombosis in a region of arterial stenosis. These events are typically studied in vitro under conditions where platelets adhere to a VWF-coated surface. Our approach assesses platelet responses in the absence of adhesion. OBJECTIVE: To characterize extent of platelet activation and erythrocyte lysis in an artificial stenosis model. METHODS: Whole blood is perfused through a length of polyetheretherketone tubing that includes an artificial stenosis, comprising narrow-bore (89-381 µm) tubing. Secretion of [14C] serotonin and hemoglobin release was measured to evaluate platelet activation and hemolysis respectively at various perfusion rates and different stenosis dimensions. RESULTS: Platelet activation and erythrocyte lysis increased progressively with increasing perfusion rate and decreasing stenosis diameter; the length of the stenosis had negligible influence. Modest platelet activation (5-10% secretion of [14C] serotonin) occurred without significant erythrocyte lysis under a limited range of perfusion conditions (4-6 mL/min flow through a 127 µm stenosis). CONCLUSIONS: Our experimental approach mimics conditions in severe arterial stenosis or a mechanical heart valve. It could be a valuable aid in the development of novel drugs to treat arterial thrombosis and in the design of heart valves.


Asunto(s)
Análisis Químico de la Sangre/métodos , Plaquetas/fisiología , Eritrocitos/metabolismo , Activación Plaquetaria/fisiología , Adhesividad Plaquetaria/fisiología , Humanos , Estrés Mecánico
7.
J Am Heart Assoc ; 6(10)2017 Oct 17.
Artículo en Inglés | MEDLINE | ID: mdl-29042425

RESUMEN

BACKGROUND: The safety of testosterone supplements in men remains unclear. In the present study, we tested the hypothesis that in young and old male spontaneously hypertensive rats (SHR), long-term testosterone supplements increase blood pressure and that the mechanism is mediated in part by activation of the renin-angiotensin system. METHODS AND RESULTS: In untreated males, serum testosterone exhibited a sustained decrease after 5 months of age, reaching a nadir by 18 to 22 months of age. The reductions in serum testosterone were accompanied by an increase in body weight until very old age (18 months). Testosterone supplements were given for 6 weeks to young (12 weeks-YMSHR) and old (21-22 months-OMSHR) male SHR that increased serum testosterone by 2-fold in young males and by 4-fold in old males. Testosterone supplements decreased body weight, fat mass, lean mass, and plasma leptin, and increased plasma estradiol in YMSHR but had no effect in OMSHR. Mean arterial pressure (MAP) was significantly higher in OMSHR than in YMSHR and testosterone supplements decreased MAP in OMSHR, but significantly increased MAP in YMSHR. Enalapril, the angiotensin-converting enzyme inhibitor, reduced MAP in both control and testosterone-supplemented YMSHR, but had a greater effect on MAP in testosterone-treated rats, suggesting the mechanism responsible for the increase in MAP in YMSHR is mediated at least in part by activation of the renin-angiotensin system. CONCLUSIONS: Taken together with previous studies, these data suggest that testosterone supplements may have differential effects on men depending on age, cardiovascular and metabolic status, and dose and whether given long-term or short-term.


Asunto(s)
Presión Arterial/efectos de los fármacos , Terapia de Reemplazo de Hormonas/efectos adversos , Hipertensión/fisiopatología , Testosterona/toxicidad , Adiposidad/efectos de los fármacos , Factores de Edad , Envejecimiento , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Antihipertensivos/farmacología , Modelos Animales de Enfermedad , Enalapril/farmacología , Estradiol/sangre , Hipertensión/sangre , Hipertensión/tratamiento farmacológico , Leptina/sangre , Masculino , Ratas Endogámicas SHR , Sistema Renina-Angiotensina/efectos de los fármacos , Factores de Riesgo , Testosterona/administración & dosificación , Testosterona/sangre , Testosterona/deficiencia , Aumento de Peso/efectos de los fármacos
8.
Free Radic Biol Med ; 52(6): 1101-10, 2012 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-22281400

RESUMEN

Four cysteine residues (Cys866, Cys917, Cys1094, and Cys1105) have direct roles in cooperatively regulating Janus kinase 2 (JAK2) catalytic activity. Additional site-directed mutagenesis experiments now provide evidence that two of these residues (Cys866 and Cys917) act together as a redox-sensitive switch, allowing JAK2's catalytic activity to be directly regulated by the redox state of the cell. We created several variants of the truncated JAK2 (GST/(NΔ661)rJAK2), which incorporated cysteine-to-serine or cysteine-to-alanine mutations. The catalytic activities of these mutant enzymes were evaluated by in vitro autokinase assays and by in situ autophosphorylation and transphosphorylation assays. Cysteine-to-alanine mutagenesis revealed that the mechanistic role of Cys866 and Cys917 is functionally distinct from that of Cys1094 and Cys1105. Most notable is the observation that the robust activity of the CC866,917AA mutant is unaltered by pretreatment with dithiothreitol or o-iodosobenzoate, unlike all other JAK2 variants previously examined. This work provides the first direct evidence for a cysteine-based redox-sensitive switch that regulates JAK2 catalytic activity. The presence of this redox-sensitive switch predicts that reactive oxygen species can impair the cell's response to JAK-coupled cytokines under conditions of oxidative stress, which we confirm in a murine pancreatic ß-islet cell line.


Asunto(s)
Cisteína/genética , Diabetes Mellitus/metabolismo , Células Secretoras de Insulina/metabolismo , Janus Quinasa 2/metabolismo , Mutación/genética , Animales , Dominio Catalítico/genética , Línea Celular , Diabetes Mellitus/patología , Modelos Animales de Enfermedad , Ditiotreitol/farmacología , Activación Enzimática/efectos de los fármacos , Peróxido de Hidrógeno/farmacología , Células Secretoras de Insulina/efectos de los fármacos , Células Secretoras de Insulina/patología , Janus Quinasa 2/genética , Ratones , Mutagénesis Sitio-Dirigida , Oxidación-Reducción , Estrés Oxidativo , Fosforilación/efectos de los fármacos , Factor de Transcripción STAT5/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA